Plasma bupivacaine concentrations were measured in 45 children, whose ages ranged from 4 months to 12 years, following administration of caudal epidural analgesia. Using 3 mg/kg of bupivacaine 0.25%, mean blood levels of 1.2-1.4 JAg/ml were reached, which are well within the limits of projected toxic levels. Simultaneous arterial and venous sampling showed a small but significant difference between these two sampling sites for the first fifteen minutes.
METHODS
The patients, aged from 4 months to 12 years, were undergoing elective lower abdominal surgery. They were premedicated with papaveretum 0.4 mg/kg and hyoscine 0.008 mg/kg. Children under one year of age were premedicated with atropine 0.02 mg/kg. They were anaesthetised with thiopentone, nitrous oxide and relaxant.
Following intubation bupivacaine 3 mg/kg in a 0.250/0 solution was injected by the caudal route after ensuring that blood or spinal fluid could not be aspirated from the needle. This was done using a disposable 23 G needle with minimal advancement up the sacral canal following puncture of the sacrococcygeal membrane.
Blood samples not exceeding 1.0 ml were taken using a heparinized syringe, before the injection of local anaesthetic, and at 5, 10, 15, 20, 30, 45 and 60 minutes. These were assayed using high performance liquid chromatography3 which requires only small sample volumes, an important consideration in small patients.
In 18 of the 45 patients studied, simultaneous arterial and venous sampling was achieved Anaesthesia and Intensive Care, Vol. 11, No. 1, February, 1983 using an artery and vein on the same arm.
The patients were divided into 4 age groups for comparison -less than 1 year, 1 and 2 years, 3 to 5 years and over 5 years.
The results for each age group were tabled and the mean and the standard deviation for each time interval calculated. Student's I-test was applied to compare mean plasma levels and mean peak times at which they occurred between any pair of age groups, and to compare arterial and venous concentrations. •older than 5 years).
RESULTS
A total of 45 patients were studied. Their age distribution is shown in Table 1 . In Figure 1 the mean plasma bupivacaine concentration is plotted against time for each of these groups. gives the mean bupivacaine concentrations and standard deviation for each age group. There was no significant difference in the mean plasma concentrations in the different age groups. The highest individual plasma level achieved was 2 mg/kg, occurring in two patients at either end of the age spectrum, one in the <1-year-old group at 5 minutes and the other in the <5-year-old group at 20 minutes.
In Figure 2 the mean arterial and venous plasma concentrations are plotted against time for the 18 patients in whom simultaneous sampling was performed. The peak mean arterial levels of 1.55-1.57 JAg/ml occurred 15 to 20 minutes after injection. Table 2 gives the mean and standard deviation of the arterial and venous plasma concentration of bupivacaine for the 18 patients having simultaneous sampling. The comparison of simultaneous arterial and venous bupivacaine concentrations confirms that the difference is statistically significant (p <0.01) during the first 15 minutes.
Although a well controlled assessment of the level of the"block could not be established in all patients, those that were adequately assessed within 1-2 hours of administration suggested a reliable blockade above T6.
DISCUSSION
The maximum safe dosage of bupivacaine was originally established as 2 mg/kg by extrapolation from animal experiments. Moore challenged these proposed limits in a controlled situation by using up to 400 mg bupivacaine in adult patients without signs of systemic toxicity.4 Using 225 mg of 0.75070 bupivacaine with adrenaline, he found an arterial mean peak level of 1.49 JAg/ml with venous of 1.25 ~g/m1. 5 The dose was approximately 3-4 mg/kg although he did not attach much significance to weight, age or sex. In humans plasma bupivacaine concentrations of greater than 4 ~g/ml have been postulated to carry a risk of convulsions. 6 More recently Scott has modified the idea of an absolute toxic plasma level by emphasising the relative importance of the rate of rise of the plasma concentration. The more rapid the rise the less total dose an individual can tolerate. 7 This could be explained by the concept of rate of establishing an equilibrium of bupivacaine. The more rapid the administration the less time available for binding and redistribution of the drug and so a higher unbound fraction in the plasma is achieved.
Our previous study using 2 mg/kg via the caudal epidural route established that the peak plasma concentrations reached were well within safe limits, i.e. less than 1 ~g/ml. The present study in which the dose was 3 mg/kg, further supports Moore's observations of safe clinical levels using higher than the accepted levels of 2 mg/kg via the epidural route.
As was expected, a significant difference occurred between the arterial and venous plasma levels, but that this difference was much less than anticipated and was only obvious during the first fifteen minutes after the bupivacaine was injected.
